Form 4: Teladoc Health COO Michael Waters Reports Stock Transactions
SEC Form 4
Teladoc Health's Chief Operating Officer, Michael Willem Waters, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.
Summary
- Michael Willem Waters, the Chief Operating Officer of Teladoc Health, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2024, Waters acquired 8,452 and 24,801 shares of common stock through the conversion of performance stock units and restricted stock units, respectively.
- He also acquired 25,357 performance stock units based on the issuer's 2023 financial results, vesting over time.
- On March 4, 2024, Waters disposed of 12,468 shares of common stock at a price of $14.516 per share to cover tax withholding obligations.
- Following these transactions, Waters beneficially owns 59,355 shares of common stock and various derivative securities, including 16,905 performance stock units and 49,604 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reflects routine stock transactions related to executive compensation. There's no indication of significant positive or negative sentiment.
Positives
- The vesting of performance stock units and restricted stock units indicates that Waters is incentivized to contribute to the company's success.
- The acquisition of performance stock units is based on the issuer's 2023 financial results.
Negatives
- The sale of 12,468 shares to cover tax obligations, while routine, represents a disposal of shares by a key executive.
Future Outlook
The performance stock units vest as to one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely watched by investors for insights into management's confidence in the company's future prospects.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/03/2023 | Reporting person was granted 74,405 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | Earliest transaction date; conversion of performance stock units and restricted stock units to common stock; acquisition of performance stock units. |
| 03/04/2024 | Sale of common stock to cover tax withholding obligations. |
| 03/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.